Late Recurrent Testicular Seminoma: Histological Evidence Is Required

Introduction: Over the past 3 decades, the appropriate management of metastatic germ cell tumours (GCT) has been defined by several phase III trials. Many follow-up recommendations have been published based on expert consensus. However, common clinical scenarios can still be vexing for clinicians who are less experienced at managing patients with testicular cancer. Case Report: We highlight the arduous diagnostic work-up of a suspected late relapsing metastatic GCT in a patient suffering from fatigue, weight loss and prominent retroperitoneal lymph nodes, 4 years after first-line chemotherapy for metastatic seminoma. The various explorations finally led to the diagnosis of Whipple's disease. Conclusion: This unusual clinical case strongly highlights the need to perform an exhaustive evaluation, with a biopsy, if a late recurrent GCT is suspected to avoid pointless and potentially harmful treatment.

[1]  N. Hanna,et al.  Testicular cancer: a reflection on 50 years of discovery. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  L. Einhorn,et al.  Pitfalls in management of patients with germ cell tumors and slight elevation of serum α-fetoprotein. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Patard,et al.  Compliance with guidelines and correlation with outcome in patients with advanced germ-cell tumours. , 2014, European journal of cancer.

[4]  T. Murez,et al.  [CCAFU Recommendations 2013: Testicular germ cell cancer]. , 2013, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[5]  S. Fosså,et al.  Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  S. Fosså,et al.  Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  A. Horwich,et al.  tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial , 2011 .

[8]  A. Horwich,et al.  EAU guidelines on testicular cancer: 2011 update. , 2011, European urology.

[9]  F. Fenollar,et al.  Whipple's disease. , 2007, The New England journal of medicine.

[10]  S. Fosså,et al.  Late relapses of germ cell malignancies: incidence, management, and prognosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Fosså,et al.  Late recurrences of germ cell malignancies: a population-based experience over three decades , 2006, British Journal of Cancer.

[12]  F. Algaba,et al.  EAU Guidelines on Testicular Cancer , 2001, European Urology.

[13]  Einhorn,et al.  Testicular cancer: an oncological success story. , 1997, Clinical Cancer Research.

[14]  P. Wilkinson,et al.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Bianchi [Whipple's disease]. , 1962, Minerva medica.

[16]  S. Culine,et al.  [CCAFU Recommendations 2013: Testicular germ cell cancer]. , 2013, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.